Home
Live Updates
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission : vimarsana.com
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
– Designation is an important step toward bringing this potentially life-changing therapy to European patients –
– EU Orphan Drug Designation is the first regulatory designation for a gorilla...
Related Keywords
United States ,
Stevenm Harasym ,
Helen Sabzevari ,
Exchange Commission ,
Prnewswire Precigen Inc ,
Precigen Inc ,
European Commission ,
Drug Administration ,
Nasdaq ,
Drug Designation For The Company ,
European Union ,
Committee For Orphan Medicinal Products ,
European Medicines Agency ,
Drug Designation ,
Orphan Drug Designation ,
United States Food ,
Breakthrough Therapy Designation ,
Orphan Medicinal ,
Biologics License Application ,
Advancing Medicine ,
Annual Report ,
Otolaryngol Head Neck Surg ,
Recurrent Respiratory Papillomatosis ,
Developing Country Review ,
Health Med Ther ,
Head Neck Surg ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.